🔗 Share this article

An intervention that was once thought of as a achievement of science fiction has overcome severe and terminal leukaemias in some patients, doctors report.

The Science Powering the Breakthrough

The treatment involves precisely editing the genetic code in lymphocytes to convert them into a malignancy-combating "living drug".

The research group harnessed a method referred to as molecular letter editing.

"Molecular units are the language of life," notes the investigation.

The quartet of genetic units – adenine (A), cytosine (C), guanine (G) and thymine (T) – are the building blocks of our genome. Base editing allows scientists to target a exact part of the DNA sequence and modify the chemical makeup of just one base, converting it from one type to another and rewriting the cellular programming.

Clinical Results and Stories

To date, an additional eight children and two mature individuals with T-cell acute lymphoblastic leukaemia have been treated, with a clear 64% of patients achieving remission.

These immune cells are designed as the immune system's defenders – seeking out and destroying threats – but in T-ALL, they become malignant.

For these patients, drug treatments and bone marrow transplants had not worked. Outside of the experimental medicine, the final possibility was symptom management.

The first person to receive the treatment was in several months in the hospital. Today, her cancer is cleared and she requires just annual check-ups.

The Mechanism of Action

The team wanted to harness the inherent ability of unmodified lymphocytes to seek out and destroy threats and use it to combat the malignancy.

This was a tricky feat. They had to genetically modify the good T-cells to attack the bad ones without the therapy causing self-destruction.

The protocol entailed multiple base edits:

• Turning off the T-cells' natural attack function.
• Removing a chemical marking known as CD7 to avoid therapy self-destruction.
• Adding an "protective shield" to shield against being killed by chemo drugs.
• Programming the modified T-cells to target anything with the CD7 identifier.

The modified cells is infused into recipients. If leukaemia is undetectable after 28 days, then patients receive a bone marrow transplant to reconstitute their immune system.

"Not long ago, this could be called futurism," commented a professor involved in the research. "It's a deep, intensive treatment, yet if effective, the results are excellent."

Study Results

The research, detailed in a major medical journal, reports the findings of the initial eleven participants.

It shows that 9 out of 11 reached a complete molecular remission that allowed them to undergo a stem cell transplant.

Seven continue to be cancer-free between three months and three years following the intervention.

A primary concern of treatment includes infections while the body's defences is wiped out.

For two patients, the cancer ceased to express its CD7 identifier, allowing it to hide from the treatment and rebound in the body.

Future Outlook

"Considering the severity of this variant of cancer, this constitutes quite striking clinical results," commented a bone marrow transplant specialist associated with the study.

"Results have demonstrated powerful anti-cancer activity in patients that had exhausted other options – it's a very powerful approach."

Regarding the advancement, a senior medical officer from a stem cell charity remarked: "Given that these patients had a low chance of survival before the trial, these results offer optimism that similar interventions will progress further and be offered to more patients."